File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12185-010-0724-4
- Scopus: eid_2-s2.0-78751591483
- PMID: 21107769
- WOS: WOS:000285152900005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia
Title | Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia |
---|---|
Authors | |
Keywords | Allogeneic Autologous Hematopoietic stem cell transplantation Natural killer cell lymphoma |
Issue Date | 2010 |
Citation | International Journal Of Hematology, 2010, v. 92 n. 5, p. 702-707 How to Cite? |
Abstract | Natural killer (NK) cell lymphomas and leukemias are aggressive neoplasms. Clinically, they can be classified into nasal, non-nasal and lymphoma/leukemia subtypes. Treatment results are unfavorable. High-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) may improve patient outcome. For autologous HSCT, a critical review of the literature shows that most patients with nasal NK cell lymphoma in complete remission (CR) appear to do well without HSCT. However, patients with refractory diseases and untreated relapses have poor outcome with HSCT. Therefore, identification of patients with nasal NK cell lymphoma in CR who are at high risk of relapse may be necessary before autologous HSCT can be recommended. Patients with disseminated nasal NK cell lymphoma, non-nasal NK cell lymphoma and NK cell leukemia have poor outcome with autologous HSCT. Allogeneic HSCT may be beneficial to these patients. Most of the reported cases have been performed from HLA-identical sibling donors, and data on alternative HSC sources including matched unrelated donors and umbilical cord blood are very limited. Continuous efforts should be devoted to risk stratification for identifying high-risk individuals for HSCT, and defining the optimal conditioning regimen for NK cell lymphomas. © 2010 The Japanese Society of Hematology. |
Persistent Identifier | http://hdl.handle.net/10722/163355 |
ISSN | 2023 Impact Factor: 1.7 2023 SCImago Journal Rankings: 0.594 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwong, YL | en_US |
dc.date.accessioned | 2012-09-05T05:30:27Z | - |
dc.date.available | 2012-09-05T05:30:27Z | - |
dc.date.issued | 2010 | en_US |
dc.identifier.citation | International Journal Of Hematology, 2010, v. 92 n. 5, p. 702-707 | en_US |
dc.identifier.issn | 0925-5710 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163355 | - |
dc.description.abstract | Natural killer (NK) cell lymphomas and leukemias are aggressive neoplasms. Clinically, they can be classified into nasal, non-nasal and lymphoma/leukemia subtypes. Treatment results are unfavorable. High-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) may improve patient outcome. For autologous HSCT, a critical review of the literature shows that most patients with nasal NK cell lymphoma in complete remission (CR) appear to do well without HSCT. However, patients with refractory diseases and untreated relapses have poor outcome with HSCT. Therefore, identification of patients with nasal NK cell lymphoma in CR who are at high risk of relapse may be necessary before autologous HSCT can be recommended. Patients with disseminated nasal NK cell lymphoma, non-nasal NK cell lymphoma and NK cell leukemia have poor outcome with autologous HSCT. Allogeneic HSCT may be beneficial to these patients. Most of the reported cases have been performed from HLA-identical sibling donors, and data on alternative HSC sources including matched unrelated donors and umbilical cord blood are very limited. Continuous efforts should be devoted to risk stratification for identifying high-risk individuals for HSCT, and defining the optimal conditioning regimen for NK cell lymphomas. © 2010 The Japanese Society of Hematology. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | International Journal of Hematology | en_US |
dc.subject | Allogeneic | - |
dc.subject | Autologous | - |
dc.subject | Hematopoietic stem cell transplantation | - |
dc.subject | Natural killer cell lymphoma | - |
dc.subject.mesh | Drug Therapy | en_US |
dc.subject.mesh | Hematopoietic Stem Cell Transplantation | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Killer Cells, Natural - Pathology | en_US |
dc.subject.mesh | Leukemia - Diagnosis - Therapy | en_US |
dc.subject.mesh | Lymphoma - Diagnosis - Therapy | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Transplantation, Autologous | en_US |
dc.subject.mesh | Transplantation, Homologous | en_US |
dc.subject.mesh | Treatment Outcome | en_US |
dc.title | Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia | en_US |
dc.type | Article | en_US |
dc.identifier.email | Kwong, YL:ylkwong@hku.hk | en_US |
dc.identifier.authority | Kwong, YL=rp00358 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1007/s12185-010-0724-4 | en_US |
dc.identifier.pmid | 21107769 | - |
dc.identifier.scopus | eid_2-s2.0-78751591483 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-78751591483&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 92 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.spage | 702 | en_US |
dc.identifier.epage | 707 | en_US |
dc.identifier.isi | WOS:000285152900005 | - |
dc.publisher.place | Japan | en_US |
dc.identifier.scopusauthorid | Kwong, YL=7102818954 | en_US |
dc.identifier.citeulike | 8337650 | - |
dc.identifier.issnl | 0925-5710 | - |